

Hard to Treat Diseases, Inc. (HTDS) Reports from Mina Mar's 2nd Annual Shareholder's Conference

BELGRADE, SERBIA, April 21, 2010-- Hard to Treat Diseases, Inc. (HTDS:PK; <http://www.htdsmedical.com>) is pleased to report that HTDS team of Slavica Bio Chem (www.slavicabiochem.com) and Collagena Skin Care (http://collagenna-usa.com/1_5/) divisions have presented their results at the 2nd annual Shareholder and Business Conference of Mina Mar Group held in Toronto on Friday April 9, 2010 (<http://www.minamargroup.com/conference.php>).

After words of introduction and welcome shareholders were invited to watch company presentations and speak to company CEOs directly, to ask questions, to hear, see and feel the endless hard work that went into their companies and the opportunities afforded. It was also these issuers way of expressing gratitude for the support received and allows them to unveil future plans.

Dr. Sanja Pekovic, Chief Project Scientist of Slavica BioChem division said, "This Conference was an excellent opportunity to meet and greet many HTDS shareholders that came by the HTDS booth. We got a chance directly to speak with our shareholders and explain them our scientific efforts in searching for new therapeutic approaches that will give the hope to millions of patients suffering from traumatic brain and spinal cord injuries and multiple sclerosis disease. Many of them had some members of family or close friends with such health problems, and we were happy to share with them our achievements and knowledge, and the latest news in research that we got attending the 8th World Congress on the Brain Injury, held in Washington, DC, March 10-14, 2010, which was the largest gathering of international professionals working in the field of brain injury."

"Also", Dr. Pekovic added: "This Conference was a chance to meet colleagues from other Companies and HTDS subsidiaries, exchange experience with them, and learn more about opportunities that business with shares can offer from the leaders in this field."

At the same HTDS desk shareholders were able to see the samples of Collagena Skin Care products. Michael Arnkvorn, the president and CEO of Collagena Skin Care HTDS team said: "Collagenna Skin Care is part of a new generation of cosmetics that use only natural source, created using pure active ingredients (100% Soluble Native Marine Collagen), designed to nourish, repair and rejuvenate the essential ingredients of the skin. Our products are the result of extensive research and development by Canadian scientists. No parabens and no animal testing. It is the ultimate in skin care for people who care about what they put onto their skin and into their bodies."

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. **(THE COMPANY INTENDS TO START SUBSCRIBING TO PINK SHEETS SHORTLY)** Its IR company web site section "CLIENT SUPPORT" TAB <http://www.minamargroup.net/> or this direct link <http://minamarmarketinggroup.helpserve.com/> should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk